Published in J Infect Dis on April 01, 1976
Cell suppression in PPD-induced blast specific response of human peripheral blood lymphocytes. Clin Exp Immunol (1976) 1.18
Time of lymphocyte response after onset of tularemia and after tularemia vaccination. J Clin Microbiol (1979) 1.14
Mitogenic analysis of murine B-cell heterogeneity. J Exp Med (1978) 1.13
Cellular hypersensitivity to tuberculin in BCG-revaccinated persons studied by skin reactivity, leucocyte migration inhibition and lymphocyte proliferation. Clin Exp Immunol (1980) 0.80
Generation of a soluble immune response suppressor factor (IRSF) by unstimulated leukocytes of healthy subjects. Clin Exp Immunol (1981) 0.77
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Defining criteria for autoimmune diseases (Witebsky's postulates revisited) Immunol Today (1993) 3.81
Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A (1977) 3.31
Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy (1978) 3.08
Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A (1976) 2.82
A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol (1968) 2.66
Cellular basis of regulation of expression of idiotype. I. T-suppressor cells specific for MOPC 460 idiotype regulate the expression of cells secreting anti-TNP antibodies bearing 460 idiotype. J Exp Med (1979) 2.53
Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol (1979) 2.39
Mitogenic effect of bacterial peptidoglycans possessing adjuvant activity. J Immunol (1975) 2.15
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science (1993) 1.96
Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A (1975) 1.91
Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol (1992) 1.88
Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. Nature (1981) 1.85
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol (1985) 1.82
Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol (1980) 1.76
Cellular basis of regulation of expression of idiotype. II. Immunity to anti-MOPC-460 idiotype antibodies increases the level of anti-trinitrophenyl antibodies bearing 460 idiotypes. J Exp Med (1979) 1.76
Failure of endotoxin to increase nonspecific resistance to infection of lipopolysaccharide low-responder mice. Infect Immun (1976) 1.71
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol (1993) 1.70
Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol (1984) 1.70
Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein. Proc Natl Acad Sci U S A (1984) 1.67
Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A (1978) 1.66
Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol (1979) 1.65
Blastic transformtion of mouse spleen lymphocytes by a water-soluble mitogen extracted from Nocardia. Proc Natl Acad Sci U S A (1974) 1.62
The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis (1978) 1.59
Immune response to levan. I. Kinetics and ontogeny of anti-levan and anti-inulin antibody response and of expression of cross-reactive idiotype. J Immunol (1978) 1.57
Proteases as mitogens. The Effect of trypsin and pronase on mouse and human lymphocytes. Exp Cell Res (1974) 1.56
Isolation of mitogenic and adjuvant active fractions from various species of Nocardiae. Infect Immun (1975) 1.54
Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol (1982) 1.53
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
Identification of a new V kappa gene family that is highly expressed in hybridomas from an autoimmune mouse strain. J Immunol (1990) 1.46
Conditions that induce tolerance in mature CD4+ T cells. J Exp Med (1997) 1.45
Mitogenic effect of a water-soluble extract of Nocardia opaca: a comparative study with some bacterial adjuvants on spleen and peripheral lymphocytes of four mammalian species. J Immunol (1974) 1.40
Enhancement of nonspecific immunity to bacterial infection by cord factor (6,6'-trehalose dimycolate). J Infect Dis (1977) 1.40
Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol (1977) 1.36
Preparation and biological properties of water-soluble adjuvant fractions from delipidated cells of Mycobacterium smegmatis and Nocardia opaca. Infect Immun (1973) 1.35
Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. J Infect Dis (1980) 1.35
Nonspecific activation of murine spleen cells in vitro by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine). Cell Immunol (1977) 1.35
Immune response to levan. III. The capacity to produce anti-inulin antibodies and cross-reactive idiotypes appears late in ontogeny. J Immunol (1979) 1.34
A human T-independent B lymphocyte mitogen extracted from Nocardia opaca. J Immunol (1976) 1.33
The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol (1978) 1.33
Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol (1987) 1.29
Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis (1981) 1.27
In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol (1978) 1.26
Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A (1982) 1.26
Central pyrogenic activity of muramyl dipeptide. J Exp Med (1980) 1.26
Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). J Immunol (1978) 1.25
Blast transformation of rabbit B-derived lymphocytes by a mitogen extracted from Nocardia. J Immunol (1975) 1.25
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. J Med Chem (1982) 1.25
Neonatal treatment with low doses of anti-idiotypic antibody leads to the expression of a silent clone. J Exp Med (1981) 1.24
Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant. Biochem Biophys Res Commun (1983) 1.23
Biological study of a nontoxic, water-soluble immunoadjuvant from mycobacterial cell walls. Proc Natl Acad Sci U S A (1972) 1.22
[Serological evolution of infection by Plasmodium malariae: variations of fluorescent antibody titre after radical treatment]. Bull World Health Organ (1969) 1.22
Tolerance to thyroglobulin by activating suppressor mechanisms. Ann N Y Acad Sci (1982) 1.22
Polyclonal activation of human B lymphocytes by Nocardia water soluble mitogen (NWSM). Immunol Rev (1979) 1.19
Murine V kappa gene expression does not follow the VH paradigm. J Exp Med (1989) 1.19
Cell suppression in PPD-induced blast specific response of human peripheral blood lymphocytes. Clin Exp Immunol (1976) 1.18
Presence and subcellular localization of two distinct mitogenic fractions in the cells of Nocardia rubra and Nocardia opaca: preparation of soluble mitogenic peptidoglycan fractions. Infect Immun (1976) 1.18
Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res (1991) 1.18
The fluorescent antibody technique in the estimation of immunity in patients infected with Plasmodium malariae. Trans R Soc Trop Med Hyg (1966) 1.17
[The value of the immunofluorescent reaction in the detection of asymptomatic parasitemia due to Plasmodium malariae]. Bull World Health Organ (1967) 1.17
Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan. J Exp Med (1981) 1.16
Localization and fate of 51-Cr-labeled somatic antigens of smooth and rough Salmonellae. Ann N Y Acad Sci (1966) 1.14
Regulation of the anti-inulin antibody response by a nonallotype-linked gene. J Exp Med (1980) 1.14
Mitogenic analysis of murine B-cell heterogeneity. J Exp Med (1978) 1.13
Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol (2001) 1.13
Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP). Ann Immunol (Paris) (1977) 1.13
Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med (1977) 1.12
Increased resistance and depressed delayed-type hypersensitivity to Listeria monocytogenes induced by pretreatment with lipopolysaccharide. Infect Immun (1981) 1.11
Genetic and cellular regulation of the expression of specific antibody idiotypes in the anti-polyfructosan immune response. Ann Immunol (Paris) (1979) 1.10
Transfer of antigenic macromolecules from macrophages to lymphocytes. I. Autoradiographic and quantitative study of ( 14 C)endotoxin and ( 125 I)haemocyanin transfer. Immunology (1972) 1.09
Nonspecific immunostimulant activities of synthetic trehalose-6,6'-diesters (lower homologs of cord factor). Infect Immun (1978) 1.08
Nonspecific enhancement of host defenses against infection: experimental evidence of a new order of efficacy and safety. Surgery (1981) 1.08
Anti-immunoglobulin antibodies. I. Expression of cross-reactive idiotypes and Ir gene control of the response to IgG2a of the b allotype. J Exp Med (1980) 1.08
Absence of binding of MDP, a synthetic immunoadjuvant, to anti-peptidoglycan antibodies. J Immunol (1978) 1.06
Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. J Immunol (1978) 1.06
Idiotypic determinants of rabbit B- and T-derived lymphocytes. Immunol Rev (1977) 1.04
Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. J Exp Med (1986) 1.03
Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells. J Immunol (1998) 1.03
In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde. J Infect Dis (1978) 1.03
[Protective effects of bacterial immunostimulants in mice infected by "Klebsiella pneumoniae" resistant to antibiotics after mutation or by plasmid transfer]. Ann Immunol (Paris) (1975) 1.02
Immune response to levan. II. T independence of suppression of cross-reactive idiotypes by anti-idiotype antibodies. J Immunol (1979) 1.02
Past, present and future of the synthetic immunoadjuvant MDP and its analogs. Biochem Pharmacol (1978) 1.02
Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc (1979) 1.02
Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun (1987) 1.02
Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms. Cell Immunol (1987) 1.02
Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein. Vaccine (1998) 1.01
In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol (1979) 1.00
Protective effects of delipidated mycobacterial cells and purified cell walls against Ehrlich carcinoma and a syngeneic lymphoid leukemia in mice. Cancer Res (1973) 1.00
DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus. Viral Immunol (1996) 0.99
Studies on visceral Leishmania tropica infection in BALB/c mice. I. Clinical features and cellular changes. Clin Exp Immunol (1981) 0.99